Drugs / Anti CD56-CAR T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05941156 | May 2023 → May 2026 | T-cell and NK-cell neoplasm, extranodal nasal NK/T cell lymphoma | The Affiliated Hospital of Xuzhou Medical University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-CD56-CAR-T | “Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell Leukemia” NCT05941156 ↗ |
| Action | Deplete | “CD56-CAR T cells can kill CD56+ neuroblastoma, glioma, and SCLC tumor cells in vitro coculture” NCT05941156 ↗ |
| Modality | Cell therapy | “CD56 CAR T cells” NCT05941156 ↗ |
| Route | Other | “Anti CD56-CAR T cells were transfused back to the patient 2 days after the end of chemotherapy.” NCT05941156 ↗ |